TIMI Study Group

TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online. timi.org/40th-anniversa…

CAD polygenic risk score predicts significantly higher ASCVD risk in low-clinical risk individuals that would merit statin initiation. sciencedirect.com/science/articl…

DOAC Score also works for warfarin to stratify patients by bleeding risk, out-performing the HAS-BLED score in both a pooled RCTs and a large registry. @rgiugliano clinicalkey.com/#!/content/pla…

Potency of LDL-C lowering matters, so does timing! New analysis from FOURIER & OLE published in @EJPC shows that initiation of #evolocumab ~2 yrs earlier results in a 24% lower rate of complex coronary revasc through 8 yrs @brianbergmark @rgiugliano academic.oup.com/eurjpc/advance…

@BrianBergmark @rgiugliano

Based on data from CORE-TIMI 72a & CORE2-TIMI 72b, the FDA has approved #olezarsen, an antisense oligonucleotide that inhibits the production of apolipoprotein C-III, to ↓ triglycerides & risk of acute pancreatitis in adults w/severe hypertriglyceridemia. fda.gov/drugs/news-eve…

In patients with high-risk diabetes w/o prior MI or stroke in VESALIUS-CV trial, intensive LDL-C lowering w/ #evolocumab led to large reductions in risk of CV events and lower mortality. @EBohula @rgiugliano #ADA26 diabetesjournals.org/care/article-a…

Severe hypertriglyceridemia+diabetes=↑ risk for acute pancreatitis, a potentially life-threatening condition. In a high-risk population, #olezarsen ↓ TGs by 58–65% on top of standard therapy, w/NNT of only 16 to prevent 1 pancreatitis event over 12 months #ADA26 @YumiKangEndo

In data from 25,090 patients from the #FOURIER trial, very low Lp(a) levels were not associated with an increased risk of most adverse safety outcomes, except a small increase in the risk of T2DM. @DrM_ODonoghue @rgiugliano academic.oup.com/eurheartj/adva…

Coverage in @MassGeneralNews of @NatureMedicine paper out now showing #dapagliflozin reduces risk of developing HF in genetically predisposed individuals @marstonMD massgeneralbrigham.org/en/about/newsr…

New data from CORE-TIMI72a & CORE2-72b trials reported at #EAS2026 highlighted that #Olezarsen reduces risk of #AcutePancreatitis in people with very high #triglyceride levels. Find out more on Triglyceride Forum… triglycerideforum.org/meeting-report… #apoC3 @AndreZimerman @TIMIStudyGroup

AF pts in 4 RCTs from COMBINE-AF show #DOACs had a favorable net clinical benefit over warfarin using a patient-weighted composite clinical outcome. Out now in @NEJMEvidence @rgiugliano evidence.nejm.org/doi/10.1056/EV…

Coverage in @AMJ_Reviews of @BrianBergmark's #EuroPCR presentation on PCI vs. CABG in left main disease. emjreviews.com/en-us/amj/inte…

One of my favorite projects at TIMI. While exploratory, our findings support the concept that lowering LDL-C through PCSK9i may prevent the formation and progression of arterial aneurysms, including AAA. Now in @CircAHA @PrakritiGaba @marstonMD @BrianBergmark @TIMIStudyGroup

Delighted to host Christian Ruff @TIMIStudyGroup @nyulangone for Cardioloyy Grand Rounds. The current and future state of Factor XI inhibition for #afib

Coverage in @CardiologyToday of @BrianBergmark's EuroPCR #VESALIUS presentation #evolocumab @ebohula @rgiugliano healio.com/news/cardiolog…

In #VESALIUS-CV, Lp(a) was associated with risk of major coronary events and helped identify those with larger absolute benefit from #evolocumab. LBCT presentation at @EASCongress and online now at @CircAHA @rgiugliano @EBohula ahajournals.org/doi/10.1161/CI…

Congratulations to Senior TIMI Biostatistician Andrea Bellavia, PhD, who was awarded the Teaching Citation Award from the Harvard T.H. Chan School of Public Health for excellence as a Lecturer in Biostatistics! @HarvardChanSPH

Similar 10-year survival following PCI vs CABG for left main disease in combined analysis of SYNTAX, PRECOMBAT, NOBLE, and EXCEL trials. @BrianBergmark #EuroPCR

Coverage in @TCTMD of @BrianBergmark 's #EuroPCR presentation from VESALIUS-CV (TIMI 66) #evolocumab @EBohula @rgiugliano tctmd.com/news/evolocuma…

In prior PCI subgroup of VESALIUS-CV trial, #evolocumab significantly reduced MACE, including 50% reduction in MI. Presented at #EuroPCR and out now in @CircAHA @BrianBergmark @EBohula @rgiugliano ahajournals.org/doi/10.1161/CI…